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A B S T R A C T Cultured endothelial cells provide a model for the study of interactions of vasoactive peptides with endothelium. Endothelial cells cultured from veins of human umbilical cords contain both angiotensin I converting enzyme (kininase II) and angiotensinase activities. Intact monolayers of cells can both activate angiotensin I and inactivate bradykinin when the peptides are added to culture flasks in protein-free medium. Intact suspended cells or lysed cells convert angiotensin I to angiotensin II, inactivate bradykinin, and hydrolyze hippuryldiglycine to hippuric acid and diglycine. These actions are inhibited by SQ 20881, the specific inhibitor of converting enzyme. The kininase activity of endothelial cells was partially inhibited by antibody to human lung converting enzyme. Endothelial cells also inactivate longer analogs of bradykinin, such as kallidin, methionyl-lysyl bradykinin, and bradykinin coupled. covalently to 500,000 mol wt dextran. The endothelial cells retained converting enzyme activity through four successive subcultures, indicating that the enzyme is synthesized by the cells. The converting enzyme is localized on the cell surface, and it is apparently a marker for endothelial cells, since cultured human fibroblasts, smooth muscle cells, and baby hamster kidney cells do not have it. Endothelial cells also contain an aminopeptidase which hydrolyzes both angiotensin II and the synthetic substrate, a-L-aspartyl S-naphthylamide. The angiotensinase activity increased when the cells were lysed, which suggests that the enzyme is localized A portion of these results was presented at the meeting of the American Heart Assodiation in 1975.
INTRODUCTION
The vascular endothelium occupies a unique position in metabolism and transport of substances from both blood and tissues. The endothelium functions as more than a simple diffusion barrier between these compartments, because by metabolizing bloodborne peptides it can determine the fate of these materials in circulation.
The metabolism of vasoactive peptides by the lung has been studied extensively (1) (2) (3) . An enzyme, presumably on the surface of the endothelial cells (4, 5) , cleaves angiotensin I and bradykinin during passage through the pulmonary circulation. This angiotensin I converting enzyme, or kininase II, acts as peptidyldipeptidase (EC 3.4.15.1) since, by the release of a carboxyl-terminal dipeptide, it both generates angiotensin II from angiotensin I and inactivates bradykinin (6) (7) (8) .
Although the pulmonary circulation was first recognized as a major site for metabolism of bradykinin and angiotensin I, these peptides are hydrolyzed in other vascular beds, presumably by contact with the converting enzyme (9) (10) (11) (12) (13) (14) . Angiotensin II also may be cleaved during contact with vascular endothelium by an angiotensinase, since it is inactivated in the peripheral circulation and in isolated, perfused vascular beds (1) . Some investiga--tors (15) report that angiotensin II activity is lost after a single passage through coronary or renal vascular beds, but the peptide can pass through the pulmonary circulation without loss of biologic activity (1, 9, 10, 16) . Thus, it appears that enzymes that both activate and inactivate angiotensins are associated with endothelium, but they have a different distribution in the various vascular beds.
The availability of human endothelial cells in culture provided new impetus to studies of endothelial cell function. Cells derived from the veins of umbilical cords have been cultured successfully by several laboratories (17) (18) (19) . These cultures provide homogeneous cell populations that exhibit the morphologic and biochemical characteristics of endothelium in situ. We utilized cultured human endothelial cells to study the angiotensin I converting enzyme and angiotensinase activities associated with endothelium (20 (21) were elicited in goats and the IgG fraction of immune serum was isolated by precipitation with 33% ammonium sulfate and chromatography on a DEAEcellulose column. Bradykinin was coupled to soluble dextran of 500,000 mol wt that was activated with sodium meta-periodate (22) . Swine kidney converting enzyme (23) and human serum albumin were labeled with 125I by the chloramine-T method described by Freedlender et al. (24) .
Cell cultures. Endothelial cells from veins of human umbilical cords were collected according to the methods described by others (17) (18) (19) Human skin fibroblasts were cultured from skin biopsy material by the method of Taylor et al. (26) The activation of angiotensin I to II and the inactivation of kinins and angiotensin II were determined by bioassays. The bioassay technique proved to be the most satisfactory means of rapidly identifying kininase or angiotensinase activities in cell cultures and for quantitation of the enzyme activity in a small amount of material, such as the cells from a single culture flask. The estrus rat uterus was used to assay inactivation of kinins or angiotensin II or activation of angiotensin I (28). One horn from an animal pretreated with diethylstilbesterol (0.4 mg/kg) was suspended in a smooth muscle bath in Dejalon's solution2 containing atropine sulfate (1 mg/ml). Either standard peptides or test samples were injected every 5 min, and the amount of peptide in an incubation mixture was determined by comparison of the contractions with those produced by standards.
The rate of inactivation or generation was measured by incubating the cells or cell lysates with peptide substrates at 37°C in converting enzyme buffer. Aliquots were withdrawn at various times, diluted with 0.2-1 ml of saline and tested on the smooth muscle. The reaction rates were linear with time over a period of 0-30 min. Since angiotensinase in lysed cell preparations (see below) inactivated both angiotensin I and II, inactivation of bradykinin 2 DeJalon's solution contained 154 mM NaCl, 5.4 mM KCI, 0.5 mM CaCl2, 6 mM NaHCO3, and 5.5 mM glucose.
was the most reliable means of measuring converting enzyme activity. The hydrolysis of bradykinin by the cells was 80-95% inhibited by the specific inhibitor, SQ 20881 (0.1 mM).
Angiotensinase activity and its inhibition by o-phenanthroline (1 mM) was measured in cells and cell lysates by incubating them at 37°C with angiotensin II in converting enzyme buffer. Aliquots were withdrawn at various times and injected into the muscle bath as described. A decrease in the height of contraction with time of incubation was interpreted as degradation of the peptide in the reaction mixture.
Lactic dehydrogenase activity of cell fractions was measured with a Sigma assay kit (Sigma Chemical Co.). Sodium pyruvate (1.6 mM) was the substrate. The decrease in optical density at 254 nm that resulted from oxidation of DPNH (10 ,uM) was measured in a Cary model 118 spectrophotometer (Cary Instruments, Monrovia, Calif.).
Treatment of cells. Enzymatic activities were measured in monolayers of cells, suspended intact cells, cell lysates, and fractions of lysed cells that were separated by differential centrifugation.
The cell monolayers were tested for enzymatic activities after the cell surfaces were washed at least three times with 10 ml of protein-free culture medium. In some experiments SQ 20881 was added to the final wash and the monolayers were incubated with the inhibitor for 15 min at 37°C. The peptide substrates (angiotensin I and II and bradykinin) were added directly to the flasks in 10 ml of protein-free culture medium. An aliquot of 0.5 ml was immediately removed and the flasks were placed on a rocker platform in the CO2 incubator at 37°C. Aliquots were withdrawn at various times during the incubation and were kept on ice until assayed. At the end of the experiment the cells were suspended by brief treatment with 0.25% trypsin, resuspended in 5-10 ml of fresh medium containing 10%o fetal calf serum to stop the action of the trypsin, and the cells were counted in a hemocytometer. Trypan blue was added to the sample taken for counting to determine the number of viable cells. The remaining cell suspension was centrifuged at low speed (1,000-2,000 rpm) for 5 Uptake of proteins from media. To determine whether the endothelial cells took up converting enzyme from serum added to the culture medium, some cultures were grown in media that contained either 125j-labeled human serum albumin or 125I-labeled converting enzyme (24) . After 72 h of contact with the labeled materials (2,000,000 cpm/ml) the cells were detached with 0.25% trypsin and washed with protein-free medium as described above. The final cell pellet was counted in a Packard 5120 autogamma scintillation :pectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.)
Relation of enzyme activity to cell number. Initially, an aliquot of suspended cells from each experiment was counted in a hemocytometer and the cell counts were compared with DNA measurements. In five experiments the DNA content of the cultured cells was 6.1±0.3 ,ug per million cells. This figure is in close agreement with the DNA content of mammalian cells given by Lehninger (30) . Thus, to avoid errors caused by clumping of the cells during suspension and handling, the cell number was determined by the DNA content of each cell suspension.
DNA and protein determinations. An aliquot of suspended cells or a cell pellet was first treated with 0.25 ml of cold 0.5 N perchloric acid and allowed to stand in ice for 10 min. The sample was centrifuged to sediment 
RESULTS
Identification of endothelial cells. The cells cultured from human umbilical cords were examined by light and electron microscopy. Their morphology was similar to that described by others for cultured endothelium (17) (18) (19) 33) . The starting cultures were compact colonies of hexagonal cells that spread into monolayers at a relatively slow rate. Typically, 1 wk or more was required to obtain a confluent monolayer when the cells of a single cord were divided into two 250-ml flasks. Examination of the cultured cells with transmission electron microscopy revealed fibrils, pinocytotic vesicles, and the specific endothelial granules, or Weibel-Palade bodies (34) in the cytoplasm. These latter inclusions occur in endothelial cells but not in cultured smooth muscle cells or in fibroblasts which might be collected as contaminants of the endothelial cells from umbilical veins (17, 19, 25) . Fig. 1 shows the Weibel-Palade bodies and pinocytotic vesicles in cultured endothelial cells.
Endothelial cell cultures secrete a protein that is apparently specific for endothelial cells, Factor VIII antigen (35, 36) . As another means of identifying our cultures as authentic endothelial cells, this marker was measured by the immunoelectrophoretic method of Zimmerman et al. (37) . Culture fluids were collected after Fig. 2 . When the cells were suspended by treatment with trypsin or collagenase or by scraping, the kininase activity increased 10-fold but the rate ofangiotensin I conversion increased only 3-to 4-fold. Disruption of the cells by sonication or by nitrogen cavitation did not increase the activity further. Freezing and thawing of the cells decreased the activity of the kininase by nearly 70% as compared with intact cell preparations or cells lysed by sonication or nitrogen cavitation (Table III) .
Angiotensinase was not detected in intact cell monolayers during a 60-90-min incubation period.
However,angiotensin II was hydrolyzed by suspended cells at a rate of approximately 4 nmol/h per million cells. When the cells were lysed the activity of angiotensinase doubled. The inactivation of angiotensin could be partially (66-87%) inhibited by addition of o-phenanthroline (1 mM) to the reaction mixture.
The synthetic substrate hippuryl-diglycine was also used to assay the activity of converting enzyme in endothelial cells and the amount of glycyl-glycine released was measured with an amino acid analyzer. The concentration of the dipeptide product increased with the time of incubation as shown in Fig. 3 . In untreated suspended cells that were incubated with the substrate (1 mM) for 18-24 h the rate of cleavage was 17.7 nmol/h per million cells (Table IV) . While this method was not as sensitive as the bioassay methods, it confirmed that the enzyme released a dipeptide from the carboxyl terminal end of the substrate. This reaction also was inhibited by the specific inhibitor, SQ 20881, and all data are given as specific activity of the converting enzyme, i.e., the difference in activity between uninhibited and inhibited cell preparations. Suspended cells and sonicated cells had comparable enzyme activities when measured by this method. However, as indicated earlier (Table  III) , cells that were lysed by freezing and thawing several times had only a third of the activity of unfrozen cells. Although CoCl2 has been shown to enhance the activity of converting enzyme from plasma (7), addition of CoCl2 (1 mM) did not affect the activity in endothelial cells. EDTA, which inhibits the enzyme in both plasma and tissues (14) , almost completely blocked the hydrolysis of hippuryl-diglycine by endothelial cells (Table IV) .
Converting enzyme activity in other cultured cells. Baby hamster kidney cells, human skin fibroblasts, and smooth muscle cells were tested for converting enzyme activity with both bradykinin and hippuryldiglycine as substrates. Although there was kininase activity in baby hamster kidney cells and in both human fibroblasts and smooth muscle cells, the activity was not inhibited by SQ 20881 and these cells did not cleave hippuryl-diglycine. Thus, the major kininase activity was not attributed to the angiotensin I converting enzyme.
Several cultures of human endothelial cells that appeared fibroblastic after several weeks in culture were also tested. These cells were a mixture of epi- tained by cultured endothelial cells through several successive subcultures. Fig. 4 shows the enzymatic activity in two different cell lines that were tested as primary cultures and at the time of each transfer.
Although there was approximately a twofold difference in the basal level of activity, each culture retained the original activity, even after the fourth transfer. Furthermore, the converting enzyme in subcultured cells was inhibited by SQ 20881. Since such subculture starts with only one-third or one-fourth of the original culture, retention of the enzyme activity through four separate passages indicates that the cells synthesize the enzyme during growth ofthe cell monolayer.
Other substrates. The converting enzyme from human endothelial cells hydrolyzed both kallidin and methionyl-lysyl-bradykinin but at slower rates than bradykinin (Table V) . Hydrolysis of all three kinins was inhibited by SQ 20881 at a concentration of 0.1 mM (not shown). The enzyme was also active on bradykinin that was coupled at the amino terminal end to a soluble dextran of 500,000 mol wt. (This complex retained about 50% of the activity of unbound bradykinin when tested on the rat uterus.) The inactivation of the macromolecular complex was also inhibited by SQ 20881. However, the coupled peptide was inactivated more slowly than bradykinin. Cleavage of this high molecular complex suggests that the kininase is localized on the surface of the endothelial cells (Table V) .
Effect of antibody to converting enzyme. The kininase activity in endothelial cells was partially inhibited by antibody to human lung converting enzyme. When cells were incubated with the IgG fraction of goat antiserum to the human lung enzyme for 15 min before addition of bradykinin, enzyme activity decreased by approximately 45%. Incubation with antibody for 60 min did not result in any greater inhibition. In five separate experiments the concentration of antibody required for this maximal inhibition was between 45 and 100 Ug/106 cells (mean = 65.8). Fig. 5 shows an experiment where the cells were incubated with varying concentrations of the partially purified antibody for 15 min before measurement of the kininase activity by bioassay.
Fractionation of endothelial cells. Cultured endothelial cells were disrupted by N2 cavitation and fractionated by differential centrifugation at 30,000 and 100,000 g (Table VI ). All of the fractions (nuclear pellet, microsomal pellet, and high-speed supernatant) had some kininase activity, but most of the activity (80%) was found in the final, high-speed FIGuRES5 Inhibition of kininase activity of cultured human endothelial cells by antibody to human lung converting enzyme. Endothelial cells in suspension (0.5 x 108/ml) were incubated with antibody in the concentrations given on the abscissa. The kininase activity was determined with bradykinin (1 ,uM) substrate on the rat uterus. The percent inhibition of bradykinin inactivation is indicated on the ordinate. The enzyme in cells treated with normal goat serum (not shown) was not inhibited. supernatant fraction. Approximately 17% of the total activity remained in the 30,000-g pellet, presumably in association with unbroken cells. Only trace amounts of activity were recovered in the high-speed (membrane) pellet. The total amount of activity recovered relative to the crude homogenate varied between 39 and 80% in four experiments. The specific activity for both the starting material (cell homogenate) and the final supernatant fraction was approximately 20 nmol/h per mg protein.
DISCUSSION
We identified two enzymes that metabolize vasoactive peptides in the endothelial cells cultured from human veins: angiotensin I converting enzyme (kininase II) and an aminopeptidase which cleaves angiotensin II (angiotensinase A). However, our primary interests were the properties and localization of the angiotensin converting enzyme associated with endothelial cells.
The angiotensin converting enzyme occurs in both soluble and membrane-bound forms. For example, human or guinea pig plasma are sources of soluble enzyme while lung or kidney of man and experimental animals contain membrane-bound enzyme (14) . The converting enzyme in rabbit (5), rat, and hog (4, 38) lungs was identified in vascular endothelium by a combination of immunofluorescence and other immunochemical methods. When the converting enzyme was purified from homogenates of lung, however, a substantial amount of activity was in the soluble fraction (21) . In the kidney, the converting enzyme is concentrated on the brush border of epithelial cells in the proximal tubules (5, 39, 40) .
The converting enzyme in human endothelial cells was identified by measuring inactivation of bradykinin and activation of angiotensin I in vitro. Cleavage of the carboxyl terminal dipeptide from shorter peptide substrates was shown qualitatively by thinlayer chromatography and was measured quantitatively in an amino acid analyzer. Inhibition of these activities by the specific inhibitor of converting enzyme SQ 20881 (8, 14) identified the enzyme as angiotensin I converting enzyme.
The converting enzyme of endothelial cells appears to be localized on or very near the cell surface. It is readily accessible to peptide substrates, since intact cell monolayers metabolize both bradykinin and angiotensin I and the activities are inhibited by SQ 20881. Furthermore, the enzyme on intact, suspended cells is accessible to high molecular weight substances, such as the complex of bradykinin and dextran or the antibody to human lung converting enzyme. Although the suspended cells inactivate bradykinin bound to dextran more slowly than free bradykinin, the fact that the reaction is inhibited by SQ 20881 indicates that inactivation is by the converting enzyme. The inhibition of the kininase activity by antibody to human lung converting enzyme shows that the enzyme on suspended cells is available for combination with the antibody. Since lysis of the cells by sonication does not increase the activity beyond that in intact, suspended cells (Tables  III and IV) , the converting enzyme of cultured Nagatsu and co-workers (27) described an enzyme in human serum that released aspartic acid from both angiotensin II and a-L-aspartyl ,3-naphthylamide. They classified this enzyme as angiotensinase A (41) on the basis of its dependence upon calcium and inhibition by EDTA. The enzyme in endothelial cells is inhibited by another metal sequestering agent, o-phenanthroline, and it is probably angiotensinase A.
Angiotensin I1 was not inactivated during incubation with cell monolayers (Table III) , which indicates either that the angiotensinase was not active on the surface of intact cells or the level of activity was below the sensitivity of our assay. Angiotensinase activity could be detected, however, in suspended cells and it increased in lysed cells, indicating that it is probably localized within the cells.
When the cells were suspended by trypsin or collagenase treatment, kininase activity increased approximately 10-fold. Endothelial cells that were suspended by scraping contained as much converting enzyme activity as did those detached by trypsin or collagenase. Thus, it is not likely that the enzyme treatment causes the increase in activity. Since the enzyme is localized on the cell surface, this increase in enzyme activity may be due, in part, to an increase in the cell surface area. When the monolayer is adherent to the surface of the culture flask, only one surface of the cell is in contact with the bathing medium. When cells are suspended, they pull apart and assume a spherical shape. This change in shape could also change infoldings of the cell surface, but we do not have evidence to support this. Another factor that may accelerate the rate of substrate cleavage is the frequency of contact between enzyme and substrate. In experiments with cell monolayers, the medium containing the peptide is slowly moved past only one surface of the cell by agitation of the flasks on a rocker platform. When the cells are suspended, they contact the substrate on all sides during constant agitation in a metabolic shaker.
It was reported that converting enzyme in tissues such as lung or kidney is localized in a microsomal or membrane fraction (6, 14, 39) . However, the distribution of enzyme activity in fractions of homogenized tissues varies according to the organ of origin (8, 21, 23 The converting enzyme is presumably synthesized by cultured endothelial cells since the activity is retained by successive subcultures. Several pieces of evidence suggest that the converting enzyme is synthesized by endothelial cells rather than taken up from the serum added to the culture media. First, endothelial cells did not accumulate 125I-labeled converting enzyme when it was included in the culture medium. Second, several cell lines, including human fibroblasts, smooth muscle cells and baby hamster kidney cells had no significant converting enzyme activity, although they were grown in media containing serum. Finally, the converting enzyme activity was retained by successive subcultures of endothelial cells. When a particular cell line was followed from the initial (primary) culture through several transfers, no activity was lost as long as the cells retained their typical endothelial cell morphology and slow rate of growth. In several cultures, however, there was a distinct change in morphology and rate of cell growth, presumably as a result of overgrowth with fibroblastic cells. These cultures had much less converting enzyme activity than did the authentic endothelial cell cultures, which could be explained by the finding that human skin fibroblasts have little or no converting enzyme activity.
The converting enzyme in plasma and tissues is inhibited by metal sequestering agents such as EDTA or o-phenanthroline, and the activity of the enzyme from plasma is enhanced by the addition of CoC12 to the reaction mixture (7) . The enzyme from cultured endothelial cells is inhibited by EDTA and thus appears to have a similar requirement for a metal ion, but its activity is not affected by addition of CoCl2.
The homology of the converting enzyme from endothelial cells with the enzyme from human lung was not established in these experiments. However, since an antibody prepared against purified human lung converting enzyme partially inhibited kininase activity of the cultured cells, the two enzymes presumably contain some of the same antigenic determinants. It was shown previously that antibody to purified converting enzyme is not organ, but species specific (23) .
The specificity of the endothelial cell converting enzyme was studied with several kinin peptides. The deca-and undecapeptides, kallidin and methionyl-lysyl-bradykinin, are less potent than bradykinin in stimulation of smooth muscle. However, these longer analogs have a more potent vasodilator action than bradykinin when they are injected in vivo (42) . We found that bradykinin was hydrolyzed by endothelial cells at a faster rate than the longer peptides. Previously Dorer and associates (43) noted that a preparation of converting enzyme purified from hog lung cleaved kallidin and methionyl-lysyl-bradykinin more slowly than bradykinin in vitro. The prolonged in vivo actions of kallidin and methionyl-lysyl-bradykinin may be due, in part, to slower inactivation by kininase II in endothelium.
The localization of angiotensin I converting enzyme in endothelial cells of blood vessels may explain some of the actions and fate of vasoactive peptides in the systemic circulation. Although the endothelial cells of the lung can hydrolyze angiotensin I that is released by renin into venous blood, the peptide in arterial blood could be hydrolyzed by contact with endothelium in the systemic circulation or after glomerular filtration on the brush border of renal tubular cells (39) . The converting enzyme in the vessels of the peripheral circulation may be important for the regulation of flow in selected vascular beds. In this regard, Collier and Robinson found that angiotensin I injected into the forearms of human volunteers caused significant changes in blood flow of that area (12) .
Liberated angiotensin II is also metabolized in the peripheral circulation (1). The angiotensinase in endothelial cells cultured from human veins is inhibited by o-phenanthroline, and it may be angiotensinase A (41) . Angiotensinase A is an aminopeptidase that could release angiotensin III (desAsp'-angiotensin II) by cleavage of the amino terminal aspartic acid from angiotensin II. The resulting heptapeptide is less active than angiotensin II on smooth muscles but it stimulates aldosterone secretion and thus affects salt and water retention (44, 45) . The presence of enzymes that metabolize angiotensin I and II to angiotensin III (46) in cultured endothelial cells suggests that endothelium may be a site of angiotensin II generation in vivo.
